TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Glucomannan Supplementation on Body Weight in Overweight and Obese Children: A Randomized Controlled Trial
Brief Summary: Glucomannan (GNN), a water-soluble dietary fiber derived from the plant Amorphophallus konjac, is marketed for weight reduction. The exact mechanisms by which GNN might exert its actions are unclear. Nonetheless, it has been shown that GNN slows gastric emptying by forming a viscous gel of large volume, which increases the feeling of satiety. Current evidence on the effectiveness of GNN for weight reduction is sparse, and well-designed trials performed in children are needed to assess the efficacy of this modality. We aim to systematically evaluate the efficacy of GNN consumption for the management of overweight and obesity in children.


Options:
A: Arm Label: Multifaceted intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): Multifaceted intervention
B: Arm Label: Glucomannan; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Glucomannan | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Glucomannan; Assigned to Arm(s): Glucomannan | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Reduction of sugar-sweetened beverage consumption | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reduction of sugar-sweetened beverage consumption; Assigned to Arm(s): 1
D: Intervention Type: BEHAVIORAL; Name: Low glycemic index diet; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Human Papillomavirus (HPV) Associated Cancer by Intervention Studies in Teenagers Attending School Health
Brief Summary: The last ten years sexually transmitted infections (STI) have substantially increased among adolescents. STI can lead to individual suffering and have a negative effect on the future reproductive health and also increase the need for health care, thus it is important to reduce the number of STIs. HPV vaccination is included in the school-based vaccination program since 2012, a catch-up vaccination is offered to older girls and young women aged 13-25. School nurses have a key role regarding information about HPV and HPV vaccine, and the school-based vaccination program has a substantial higher coverage rate. Knowledge is an important factor associated with attitude to preventive methods against HPV. In previous studies the results indicate that young people have low awareness of HPV and the HPV vaccine. Interventions can decrease sexual risk taking and influence the intention to receive HPV vaccination and increase the use of condom.

The aim of this study is to increase primary prevention of human papillomavirus (HPV) by promoting HPV vaccination and increase condom use among upper secondary students. The aim is also to increase the knowledge about HPV, risk and prevention.


Options:
A: Arm Label: Outreach; Type: OTHER; Interventions: Other: outreach services | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: outreach services; Assigned to Arm(s): Outreach
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: AFIX In-Person Visit; Type: EXPERIMENTAL; Interventions: Other: Assessment , Feedback, Incentives, and eXchange Program | Arm Label: AFIX Webinar Visit; Type: EXPERIMENTAL; Interventions: Other: Assessment , Feedback, Incentives, and eXchange Program | Intervention Type: OTHER; Name: Assessment , Feedback, Incentives, and eXchange Program; Assigned to Arm(s): AFIX In-Person Visit, AFIX Webinar Visit
C: Arm Label: Intervention Practices; Type: EXPERIMENTAL; Interventions: Behavioral: Multimodal Vaccine Program | Arm Label: Control Practices; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multimodal Vaccine Program; Assigned to Arm(s): Intervention Practices
D: Arm Label: Education about HPV by school nurse; Type: EXPERIMENTAL; Interventions: Behavioral: Education about HPV by school nurse | Arm Label: Control group 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Education about HPV by school nurse; Assigned to Arm(s): Education about HPV by school nurse

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CITrate and Evodial for Effective Dialysis (CITED) Study
Brief Summary: It is not known whether the combination of a heparin-grafted membrane plus citrate-containing dialysate is a valid alternative to regional citrate anticoagulation. This is a cross-over non-inferiority trial comparing these two anticoagulation strategies


Options:
A: Arm Label: Dialysis without systemic heparinization; Type: EXPERIMENTAL; Interventions: Procedure: Dialysis without systemic heparinization | Intervention Type: PROCEDURE; Name: Dialysis without systemic heparinization; Assigned to Arm(s): Dialysis without systemic heparinization
B: Arm Label: EVODIAL dialyzer and Selectbag citrate; Type: EXPERIMENTAL; Interventions: Device: EVODIAL dialyzer and Selectbag citrate | Arm Label: Regional citrate anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: Regional citrate anticoagulation | Intervention Type: DEVICE; Name: EVODIAL dialyzer and Selectbag citrate; Assigned to Arm(s): EVODIAL dialyzer and Selectbag citrate | Intervention Type: DEVICE; Name: Regional citrate anticoagulation; Assigned to Arm(s): Regional citrate anticoagulation
C: Arm Label: Tinzaparin; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin administration | Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin administration | Intervention Type: DRUG; Name: Tinzaparin administration; Assigned to Arm(s): Tinzaparin | Intervention Type: DRUG; Name: Heparin administration; Assigned to Arm(s): Heparin
D: Arm Label: saline flushes; Type: PLACEBO_COMPARATOR; Interventions: Drug: two stage regional citrate | Arm Label: one stage regional citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: one stage regional citrate | Arm Label: two stage regional citrate; Type: EXPERIMENTAL; Interventions: Drug: two stage regional citrate, Drug: one stage regional citrate | Intervention Type: DRUG; Name: two stage regional citrate; Assigned to Arm(s): saline flushes, two stage regional citrate | Intervention Type: DRUG; Name: one stage regional citrate; Assigned to Arm(s): one stage regional citrate, two stage regional citrate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control
Brief Summary: This is a multi-centre, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma on markers of asthma control. The overall intent of the current study is to more fully explore the impact of mepolizumab on health-related quality of life (HR-QoL) and other measures of asthma control, including lung function.

Participants who meet the predefined criteria will be randomised to receive either mepolizumab or placebo in addition to standard of care asthma treatment. Approximately 780 participants with severe eosinophilic asthma will be screened to ensure the randomisation of 544 participants (272 participants per treatment group) into the study.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A, Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A, B, C
B: Arm Label: Mepolizumab SC; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab, Drug: SOC | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: SOC | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC | Intervention Type: DRUG; Name: SOC; Assigned to Arm(s): Mepolizumab SC, Placebo SC
C: Arm Label: MEDI528 30 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 30 mg | Arm Label: MEDI528 100 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 100 mg | Arm Label: MEDI528 300 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI528 300 mg | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI528 30 mg; Assigned to Arm(s): MEDI528 30 mg | Intervention Type: BIOLOGICAL; Name: MEDI528 100 mg; Assigned to Arm(s): MEDI528 100 mg | Intervention Type: BIOLOGICAL; Name: MEDI528 300 mg; Assigned to Arm(s): MEDI528 300 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control
Brief Summary: This is a multi-centre, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma on markers of asthma control. The overall intent of the current study is to more fully explore the impact of mepolizumab on health-related quality of life (HR-QoL) and other measures of asthma control, including lung function.

Participants who meet the predefined criteria will be randomised to receive either mepolizumab or placebo in addition to standard of care asthma treatment. Approximately 780 participants with severe eosinophilic asthma will be screened to ensure the randomisation of 544 participants (272 participants per treatment group) into the study.


Options:
A: Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: OTHER; Interventions: Biological: IMA-638 is a biologic | Intervention Type: BIOLOGICAL; Name: IMA-638 is a biologic; Assigned to Arm(s): 1
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: CAT-354 150 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 150 mg | Arm Label: CAT-354 300 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 300 mg | Arm Label: CAT-354 600 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 600 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 150 mg; Assigned to Arm(s): CAT-354 150 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 300 mg; Assigned to Arm(s): CAT-354 300 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 600 mg; Assigned to Arm(s): CAT-354 600 mg
D: Arm Label: Mepolizumab SC; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab, Drug: SOC | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: SOC | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC | Intervention Type: DRUG; Name: SOC; Assigned to Arm(s): Mepolizumab SC, Placebo SC

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations.
Brief Summary: Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy. Patient should have received at least 2 prior lines of platinum based chemotherapy. The aim of the study is to assess the efficacy and safety of olaparib tablets.


Options:
A: Arm Label: SPARC-08-038; Type: EXPERIMENTAL; Interventions: Drug: SPARC-08-038, Drug: Ref-08-038 | Arm Label: Ref-08-038; Type: ACTIVE_COMPARATOR; Interventions: Drug: SPARC-08-038, Drug: Ref-08-038 | Intervention Type: DRUG; Name: SPARC-08-038; Assigned to Arm(s): Ref-08-038, SPARC-08-038 | Intervention Type: DRUG; Name: Ref-08-038; Assigned to Arm(s): Ref-08-038, SPARC-08-038
B: Arm Label: 1/OLAPARIB; Type: EXPERIMENTAL; Interventions: Drug: OLAPARIB | Arm Label: 2/CHEMOTHERAPY; Type: ACTIVE_COMPARATOR; Interventions: Drug: Single agent chemotherapy | Intervention Type: DRUG; Name: OLAPARIB; Assigned to Arm(s): 1/OLAPARIB | Intervention Type: DRUG; Name: Single agent chemotherapy; Assigned to Arm(s): 2/CHEMOTHERAPY
C: Arm Label: Carboplatin + Paclitaxel + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Arm Label: Carboplatin + Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab
D: Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD 40mg/m2 ivgtt q4w | Arm Label: PLD + Apatinib; Type: EXPERIMENTAL; Interventions: Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd; Assigned to Arm(s): PLD + Apatinib | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w; Assigned to Arm(s): PLD

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations.
Brief Summary: Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy. Patient should have received at least 2 prior lines of platinum based chemotherapy. The aim of the study is to assess the efficacy and safety of olaparib tablets.


Options:
A: Arm Label: 1/OLAPARIB; Type: EXPERIMENTAL; Interventions: Drug: OLAPARIB | Arm Label: 2/CHEMOTHERAPY; Type: ACTIVE_COMPARATOR; Interventions: Drug: Single agent chemotherapy | Intervention Type: DRUG; Name: OLAPARIB; Assigned to Arm(s): 1/OLAPARIB | Intervention Type: DRUG; Name: Single agent chemotherapy; Assigned to Arm(s): 2/CHEMOTHERAPY
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
C: Arm Label: Olaparib tablets p.o. 300mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets p.o. twice daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olaparib 300mg tablets | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib tablets p.o. 300mg twice daily, Placebo tablets p.o. twice daily
D: Arm Label: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active comparator: Niraparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Active comparator: Niraparib; Assigned to Arm(s): Niraparib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of an Advanced Practice Nurse-led Self-management Program on Prevention of Weight Gain, Physical Activity and Medication Adherence in Patients in the First Year After Renal Transplantation
Brief Summary: The aim of this study is to investigate the effectiveness of the program in patients after renal transplantation using a randomized controlled trial design. Physical, behavioural, and clinical outcomes will be measured at baseline before randomization then 8 and 12 months later.


Options:
A: Arm Label: Group CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral adherence promotion program | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral adherence promotion program; Assigned to Arm(s): Group CBT | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management program with monthly sessions | Arm Label: Control; Type: OTHER; Interventions: Behavioral: Usual Care, containing one session | Intervention Type: BEHAVIORAL; Name: Self-management program with monthly sessions; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Usual Care, containing one session; Assigned to Arm(s): Control
C: Arm Label: With Med-O-Wheel™; Type: N/A; Interventions: N/A | Arm Label: With out Med-O-Wheel™; Type: N/A; Interventions: N/A
D: Arm Label: Multi-component Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action-focused problem-solving, Device: Electronic pillbox monitoring, dose reminders, and feedback | Arm Label: Attention control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Action-focused problem-solving; Assigned to Arm(s): Multi-component Intervention | Intervention Type: DEVICE; Name: Electronic pillbox monitoring, dose reminders, and feedback; Assigned to Arm(s): Multi-component Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Feasibility and Safety Study on Low-flow Extracorporeal CO2 Removal in Patients With Moderate ARDS to Enhance Lung Protective Ventilation
Brief Summary: Pathophysiological, experimental and clinical data suggest that an '"ultraprotective" mechanical ventilation strategy may further reduce VILI and ARDS-associated morbidity and mortality. Severe hypercapnia induced by VT reduction in this setting might be efficiently controlled by ECCO2R devices. A proof-of-concept study conducted on a limited number of ARDS cases indicated that ECCO2R allowing VT reduction to 3.5-5 ml/kg to achieve Pplat\<25 cm H2O may further reduce VILI.


Options:
A: Arm Label: One single arm; Type: EXPERIMENTAL; Interventions: Device: ECCO2R will be initiated during the 2-hour run-in time, Other: Neuromuscular blocking agents (NMBA), Device: Ventilation, Other: Level of carbon dioxide released at the end of expiration, Other: Respiratory Rate, Other: Sweep gas flow, Other: Ventilation will be adapted, Other: Respiratory rate will be adapted | Intervention Type: DEVICE; Name: ECCO2R will be initiated during the 2-hour run-in time; Assigned to Arm(s): One single arm | Intervention Type: OTHER; Name: Neuromuscular blocking agents (NMBA); Assigned to Arm(s): One single arm | Intervention Type: DEVICE; Name: Ventilation; Assigned to Arm(s): One single arm | Intervention Type: OTHER; Name: Level of carbon dioxide released at the end of expiration; Assigned to Arm(s): One single arm | Intervention Type: OTHER; Name: Respiratory Rate; Assigned to Arm(s): One single arm | Intervention Type: OTHER; Name: Sweep gas flow; Assigned to Arm(s): One single arm | Intervention Type: OTHER; Name: Ventilation will be adapted; Assigned to Arm(s): One single arm | Intervention Type: OTHER; Name: Respiratory rate will be adapted; Assigned to Arm(s): One single arm
B: Arm Label: Hyperinvasive arm; Type: EXPERIMENTAL; Interventions: Device: Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS | Arm Label: Standard arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: DEVICE; Name: Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS; Assigned to Arm(s): Hyperinvasive arm | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard arm
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: lung protective ventilation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: lung protective ventilation | Intervention Type: OTHER; Name: lung protective ventilation; Assigned to Arm(s): 1, 2
D: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ECCO2R to enable lower tidal volume mechanical ventilation; Type: EXPERIMENTAL; Interventions: Device: VV-ECCO2R to enable lower tidal volume mechanical ventilation | Intervention Type: DEVICE; Name: VV-ECCO2R to enable lower tidal volume mechanical ventilation; Assigned to Arm(s): ECCO2R to enable lower tidal volume mechanical ventilation

Answer: A